Abstract:Shao-Li Huang, 1– 3, &ast Hong-Yi Xin, 4, 5, &ast Xiao-Yan Wang, 4, 5, &ast Guang-Gui Feng, 3 Fu-Qing Wu, 3 Zhi-Peng Feng, 6 Zhou Xing, 2 Xi-He Zhang, 4, 5 Hong-Wu Xin, 4, 7, 8 Wen-Ying Luo 1 1 Medical Laboratory Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, 524400, People's Republic of China; 2 First Clinical College, Guangdong Medical University, Guangdong, 524400, People's Republic of China; 3 Clinical laboratory, Lianjiang People's Hospital, Guangdong, 524400, People's Republic of China; 4 Doctoral Scientific Research Center, Lianjiang People's Hospital, Guangdong, 524400, People's Republic of China; 5 Guangdong Medical University Affiliated Lianjiang People's Hospital, Guangdong, 524400, People's Republic of China; 6 Department of Gastroenterology, Yueyang Hospital Affiliated to Hunan Normal University, Yueyang, Hunan, 414000, People's Republic of China; 7 Laboratory of Oncology, Center for Molecular Medicine, School of Basic Medicine, Faculty of Medicine, Yangtze University, Jingzhou, Hubei, 434023, People's Republic of China; 8 Research Centre of Molecular Medicine, Medical College of Chifeng University, Chifeng, Inner Mongolian Autonomous Region, 024000, People's Republic of China &astThese authors contributed equally to this work Correspondence: Wen-Ying Luo, Medical laboratory Center, Affiliated Hospital of Guangdong Medical University, 57th South Renmin Road, Zhanjiang, 524001, People's Republic of China, Tel +86 18312728748, Email Xi-He Zhang, Doctoral Scientific Research Center, Lianjiang People's Hospital, Guangdong, 524400, People's Republic of China, Tel +86 19126491230, Email Venous thromboembolism is a condition that includes deep vein thrombosis and pulmonary embolism. It is the third most common cardiovascular disease behind acute coronary heart disease and stroke. Over the past few years, growing research suggests that venous thrombosis is also related to the immune system and inflammatory factors have been confirmed to be involved in venous thrombosis. The role of inflammation and inflammation-related biomarkers in cerebrovascular thrombotic disease is the subject of ongoing debate. P-selectin leads to platelet-monocyte aggregation and stimulates vascular inflammation and thrombosis. The dysregulation of miRNAs has also been reported in venous thrombosis, suggesting the involvement of miRNAs in the progression of venous thrombosis. Plasminogen activator inhibitor-1 (PAI-1) is a crucial component of the plasminogen-plasmin system, and elevated levels of PAI-1 in conjunction with advanced age are significant risk factors for thrombosis. In addition, it has been showed that one of the ways that neutrophils promote venous thrombosis is the formation of neutrophil extracellular traps (NETs). In recent years, the role of extracellular vesicles (EVs) in the occurrence and development of VTE has been continuously revealed. With the advancement of research technology, the complex regulatory role of EVs on the coagulation process has been gradually discovered. However, our understanding of the causes and consequences of these changes in venous thrombosis is still limited. Therefore, we review our current understanding the molecular mechanisms of venous thrombosis and the related clinical trials, which is crucial for the future treatment of venous thrombosis. Keywords: venous thromboembolism, miRNA, neutrophil extracellular traps, plasminogen activator inhibitor-1, EVs, inflammatory factor Venous thromboembolism (VTE) is a multifaceted, potentially fatal event that activates coagulation and fibrinolysis. 1 It is a condition that includes pulmonary embolism (PE) and deep vein thrombosis (DVT). 2 In addition, it is also the third most prevalent cardiovascular disease after stroke and coronary heart disease (CHD). 3 Venous thrombosis (VT) is a leading cause of mortality as well as morbidity worldwide, occurring in approximately one case in 1000 people per year in affluent nations. 4 DVT is the thrombosis that blocks the deep venous cavity, disrupting the venous reflux network and resulting in chronic deep venous dysfunction. 5,6 Furthermore, DVT is a consequence of a complicated interaction between enzymes and cellular processes, in which the endothelium, platelets, and leukocytes coordinate a pro-inflammatory state that ultimately leads to the clot formation 7 with higher mortality rate for acute DVT. 8 To date, vascular ultrasound and digital subtraction angiography are the primary techniques for diagno -Abstract Truncated-

Discovery of crucial cytokines associated with deep vein thrombus formation by protein array analysis

Biomarkers of Deep Venous Thrombosis

Preliminary clinical analysis and pathway study of S100A8 as a biomarker for the diagnosis of acute deep vein thrombosis

A Panel of Micrornas As a New Biomarkers for the Detection of Deep Vein Thrombosis

Identification of thrombotic biomarkers in orthopedic surgery patients by plasma proteomics

Relationship Between Endothelial Cell Protein C Receptor Gene 6936A/G Polymorphisms and Deep Venous Thrombosis.

Protein profile of circulating extracellular vesicles reveals biomarker candidates for diagnosis of post-traumatic deep vein thrombosis

Integrated landscape of plasma metabolism and proteome of patients with post-traumatic deep vein thrombosis

Combination of Circulating miR-125a-5p, miR-223-3p and D-dimer as a Novel Biomarker for Deep Vein Thrombosis

The potential biomarkers for thromboembolism detected by SELDI-TOF-MS

ET1 acts as a potential plasma biomarker and therapeutic target in deep venous thrombosis rat model

Blood Cell Parameters Combined with Inflammatory Markers in the Early Diagnosis of Pulmonary Embolism

Predictors and outcomes of deep venous thrombosis in patients with acute ischemic stroke: results from the Chinese Stroke Center Alliance

Clinical Risk Factors of Asymptomatic Deep Venous Thrombosis in Patients with Acute Stroke.

Microarray profile of circular RNAs identifies hsa_circ_000455 as a new circular RNA biomarker for deep vein thrombosis

The Impact of Anticoagulant Activity of Tissue Factor Pathway Inhibitor Measured by a Novel Functional Assay for Predicting Deep Venous Thrombosis in Trauma Patients: A Prospective Nested Case-Control Study

Recent Advances on the Molecular Mechanism and Clinical Trials of Venous Thromboembolism

Role of inflammatory and coagulation factors in acute deep venous thrombosis and their correlation

A vein wall cell atlas of murine venous thrombosis determined by single-cell RNA sequencing

Exploration of Effective Biomarkers for Venous Thrombosis Embolism in Behçet’s Disease Based on Comprehensive Bioinformatics Analysis

The Variation and Significance of C-reactive Protein,Interleukin-6 and D-Dimer in the Pre-therapy and Post-treatment Pe-riod of the Deep Venous Thrombosis